Fairvalue-Calculator Fairvalue-Calculator
EN DE

Precipio, Inc (PRPO) Fair Value & Analysis

Healthcare · US · Market cap $40.6M

Price$23.20
Fair Value$4.17
Upside-82.0%
Quality95/100
Evidence: Medium Range $3.46 – $4.88

Fair value as of: Jun 24, 2026

Analysis

Precipio, Inc (PRPO) currently trades at $23.20, while our model-based Fair Value estimate is $4.17 — implying the stock looks roughly 82.0% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

Open the full interactive analysis →

Similar stocks

Thermo Fisher Scientific Inc (TMO) -54% Danaher Corporation (DHR) -54% WuXi AppTec Co (WUXAY) +35% IDEXX Laboratories, Inc (IDXX) -53% Lonza Group (LZAGY) -77% Agilent Technologies, Inc (A) -52%

Frequently asked questions

Is Precipio, Inc (PRPO) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $4.17 versus a price of $23.20 — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PRPO?
Our 21-model fair value for Precipio, Inc is $4.17 (as of Jun 24, 2026), built from audited fundamentals. The current price is $23.20.
What is the quality score of PRPO?
Precipio, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.